Karyopharm Therapeutics Analyst Price Targets - Benzinga

Karyopharm Therapeutics Inc

KPTINASDAQ

Trade with Public

Trade with Public

$0.1120

-0.55-83.08%

Últ. Act.: Nov 2, 7:59 PM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Informe de acciones

© 2026 Benzinga | All Rights Reserved

Karyopharm Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Karyopharm Therapeutics (KPTI).

Price Target Range — 12 Quarters

Analyst Consensus — 7 Analysts

5Buy

2Hold

Consensus RatingOutperform# Analysts7Avg. Consensus PT$33Upside to Avg. PT+26322.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 2, 2026	Rodman & Renshaw	Michael King	Downgrade	Buy→Neutral	—
Jul 31, 2026	Piper Sandler	Edward Tenthoff	PT Cut	Overweight	$16→$7
Jul 31, 2026	HC Wainwright & Co.	Robert Burns	Downgrade	Buy→Neutral	$13→$3
May 6, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$8→$13
Apr 27, 2026	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$8→$16
Mar 30, 2026	Piper Sandler	Edward Tenthoff	PT Cut	Overweight	$12→$8
Mar 25, 2026	Baird	Michael Ulz	PT Cut	Outperform	$21→$15
Mar 25, 2026	HC Wainwright & Co.	Robert Burns	PT Cut	Buy	$15→$8
Mar 10, 2026	Rodman & Renshaw	Michael King	Initiate	Buy	$28
Feb 18, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$15
Feb 5, 2026	Cantor Fitzgerald	Yanni Souroutzidis	Initiate	Overweight	—
Nov 4, 2025	RBC Capital	Brian Abrahams	PT Cut	Outperform	$30→$19
Oct 13, 2025	HC Wainwright & Co.	Robert Burns	Upgrade	Neutral→Buy	$15
Oct 9, 2025	Piper Sandler	Edward Tenthoff	PT Cut	Overweight	$15→$12
Oct 9, 2025	Baird	Michael Ulz	PT Cut	Outperform	$25→$21
Aug 12, 2025	Baird	Michael Ulz	PT Cut	Outperform	$42→$25
Jul 16, 2025	HC Wainwright & Co.	Robert Burns	Downgrade	Buy→Neutral	—
Jul 11, 2025	HC Wainwright & Co.	Robert Burns	Assumes	Buy	$27
May 13, 2025	RBC Capital	Brian Abrahams	PT Cut	Outperform	$34→$33
May 13, 2025	Barclays	Peter Lawson	PT Raise	Overweight	$5→$10

Analyst Ratings News

PRO
Rodman & Renshaw Downgrades Karyopharm Therapeutics to Neutral

Rodman & Renshaw analyst Michael King downgrades Karyopharm Therapeutics (NASDAQ:KPTI) from Buy to Neutral.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Karyopharm Therapeutics, Lowers Price Target to $7

Piper Sandler analyst Edward Tenthoff maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Overweight and lowers the price target from $16 to $7.

Benzinga Newsdesk

This Faeth Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Wall Street analysts changed outlook on top names. Check ratings page for upgrades, downgrades, initiations. See other analysts' views on HTFL, SKYH, FTH.

Avi Kapoor

Amazon To Rally Around 55%? Here Are 10 Top Analyst Forecasts For Friday

Analysts change outlook & price targets for Crocs, Monolithic Power, Axos Financial, Amazon, Karyopharm, Apple, Guardant Health, Pagaya Tech.

Avi Kapoor

This Plexus Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday

Top Wall Street analysts upgraded IP, AXTI, REPL, and PLXS stocks with higher price targets. See what other analysts think about these stocks.

Avi Kapoor

This Edison International Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Wall Street analysts changed outlook on top names. See analyst ratings page for upgrades, downgrades, initiations. Analysts have mixed views on EIX stock.

Avi Kapoor